Invitae Corporation
NVTA
Pozycja w akcjach
#35795
Invitae Corporation operates as a medical genetics enterprise, striving to... Invitae Corporation operates as a medical genetics enterprise, striving to integrate genetic insights into mainstream medical practice to enhance healthcare outcomes for individuals in the United States, Canada, and internationally. The company provides a comprehensive suite of offerings, including genetic testing for various clinical specializations such as hereditary cancer, cardiovascular health, neurological disorders, pediatric conditions, oncology, metabolic ailments, and rare diseases, alongside digital health tools and health data services. Its clientele spans individual patients, healthcare providers, biopharmaceutical firms, and other collaborators. Established in 2010 as Locus Development, Inc., the company officially became Invitae Corporation in 2012 and is headquartered in San Francisco, California.
Cena akcji
$0.016
Ostatnia synchronizacja: 2024-03-11
Kapitalizacja rynkowa
$3.27M
Zmiana (1 dzień)
-5.33%
Zmiana (1 rok)
5,233.33%
Kraj
US
Handel Invitae Corporation (NVTA)
Kategoria
Healthcare
EPS dla Invitae Corporation (NVTA)
EPS na dzień September 2023 TTM: $-5.38
Według najnowszych raportów finansowych i ceny akcji firmy Invitae Corporation, obecny EPS (TTM) wynosi $-5.38. Na koniec roku 2022 firma miała EPS w wysokości $-13.18, wzrost w porównaniu do do EPS z roku 2021, który wynosił $-1.80.
Historia EPS dla Invitae Corporation od 2016 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-5.38 | -100.00% |
| 2023 | 0.00 | -100.00% |
| 2022 | $-13.18 | 632.22% |
| 2021 | $-1.80 | -59.73% |
| 2020 | $-4.47 | 68.05% |
| 2019 | $-2.66 | 37.11% |
| 2018 | $-1.94 | -26.79% |
| 2017 | $-2.65 | -12.25% |
| 2016 | $-3.02 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $18.62 | -446.10% |
US
|
|
| $5.65 | -205.02% |
US
|
|
| $-1.36 | -74.72% |
US
|
|
| - | - |
CN
|
|
| $5.09 | -194.61% |
US
|
